Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for
patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United
States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small …

The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-
cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib …

Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for
B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to …

Chronic lymphocytic leukemia (CLL) therapy has changed dramatically with the introduction
of several targeted therapeutics. Ibrutinib was the first approved for use in 2014 and now is …

Bruton tyrosine kinase signaling (BTK) is critical step for B-cell development and
immunoglobulin synthesis. Ibrutinib is an orally bioavailable bruton tyrosine kinase inhibitor …

Introduction Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the
treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and …

The use of novel B-cell receptor signaling inhibitors results in high response rates and long
progression-free survival in patients with indolent B-cell malignancies, such as chronic …